MICA · FIRST-LINE LEARNING NOTES
Understand, prioritise and organise follow-up
Interpret liver tests through their pattern and context. The size of an enzyme elevation alone does not establish severity or fibrosis stage.
Distinguish injury from function
Compare previous values and distinguish predominant aminotransferase elevation, cholestasis and hyperbilirubinaemia. Ask about jaundice, itching, pain, fever, confusion, bleeding and ascites. Albumin and coagulation provide functional information but have possible extrahepatic explanations; platelets may contribute to assessing advanced disease. Mild abnormalities do not exclude significant chronic liver disease.
[1]Investigate cause, not merely persistence
Quantify alcohol intake and metabolic risk; list medicines, herbal products and supplements with their timing. Aetiological assessment may include ultrasound, viral testing, iron studies and immunology according to the pattern and resources. Normal ultrasound does not resolve every possibility. Repeating the same panel without investigation is insufficient for unexplained abnormalities; consider a muscle source when aminotransferases and the clinical picture are discordant.
[1][2]Distinguish hepatocellular injury, cholestasis and impaired synthetic function. Aminotransferase elevation does not directly measure fibrosis, and normal values do not exclude chronic disease. Review alcohol, metabolic risk, medicines, traditional remedies and viral exposure. Persistent abnormalities need an aetiological and risk assessment strategy rather than repeated tests without a purpose.
[1][2]Separate acute danger from fibrosis risk
Jaundice with confusion or coagulation abnormalities, suspected sepsis or febrile biliary pain requires urgent assessment. With steatosis and cardiometabolic risk, evaluate fibrosis through a sequential pathway, for example a blood-based score followed by elastography. Such tools require clinical context and do not establish histological steatohepatitis. Discordant results or high risk warrant hepatology input.
[1][2]Follow cause and associated risks
Record the initial pattern, working cause, outstanding results and referral criteria. Review medicine safety with the prescriber and address metabolic risks in parallel. Falling aminotransferases do not prove resolution of fibrosis. Monitoring depends on diagnosis and risk rather than a uniform schedule for every abnormal liver test.
[1][2]A learning situation
FICTIONAL CASE · SELF-REFLECTION WITHOUT A SCORE
A 55-year-old patient with diabetes has ultrasound-detected steatosis and mildly elevated aminotransferases. There is no jaundice or pain. He assumes the small elevation means his liver is safe.
Which assumption needs correction?
Read the reasoning
Aminotransferase levels do not measure fibrosis stage. Consider alternative causes of steatosis, document cardiometabolic risk and assess fibrosis through the appropriate pathway. Care should address liver risk and comorbidities, rather than merely waiting for normal blood tests.
References and scope
- Guidelines on the management of abnormal liver blood tests ↗
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary ↗
Original educational synthesis for adult first-line practice. International references must be interpreted with the clinical setting and local care pathways. Independent human scientific review remains to be confirmed.